May 22, 2025

## **Notice Regarding Cancellation of Treasury Shares**

(Cancellation of treasury shares in accordance with the provisions of Article 178 of the Companies Act)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) is pleased to announce that its board of directors held today has resolved to cancel treasury shares in accordance with the provisions of Article 178 of the Companies Act.

- Reasons for the acquisition and cancellation of treasury shares
   To improve capital efficiency and further return profits to shareholders, and to implement a flexible capital policy in response to changes in the business environment.
- 2. Details of matters related to cancellation
  - (1) Type of shares to be cancelled: Common share of the Company
  - (2) Total number of shares to be cancelled: 10 million shares (13.70% of total number of shares issued before cancellation (excluding treasury shares))
  - (3) Scheduled date of cancellation: Jun 12, 2025
  - (4) Total number of shares issued after cancellation: 75,164,895 shares

(Reference information) Status of treasury shares held as of February 28, 2025

Total number of shares issued (including treasury shares): 85,164,895 shares

Number of treasury shares: 11,792,525 shares

\*The Company's shares held through Exclusive Trust for HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account (379,600 shares) are not included in the number of treasury shares.